People who struggle with daily HIV regimen should be offered long-acting injections

March 09, 2024

2 min watch

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

”
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DENVER — People with HIV who have challenges adhering to a daily oral regimen should be offered long-acting formulations of ART, study findings suggest.

An interim review of data from the phase 3 LATITUDE study — which compared daily oral ART with monthly injections — indicated that long-acting ART was significantly more effective for people who have trouble taking a daily pill.

Following a planned interim review of the data, an independent data and safety monitoring board recommended that Aadia Rana, MD, professor of medicine at the University of Alabama at Birmingham, and colleagues offer everyone in the trial long-acting ART.

“This study is important because it really broadens the types of patients who could receive injectable monthly cabotegravir-rilpivirine,” Rana said in this video from the Conference on Retroviruses and Opportunistic Infections.

Reference:

• Rana A, et al. Abstract 212. Presented at: Conference on Retroviruses and Opportunistic Infections; March 3-6, 2024; Denver.

Published by:

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

”
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio